dyspnea perception in patients with advanced lung disease
Conditions
Brief summary
Safety and tolerability of a single dose of inhaled furosemide assessed as the incidence and nature of all reported treatment-related adverse events.
Detailed description
The effect of examined substances to suppress dyspnoea will be evaluated by changing to a visually analog scale (VAS) and the Borg scale. Changes on both steps will be evaluated statistically at the level of 5% probability and it will be determined whether the changes have achieved minimum clinically relevant changes against the default values. As a minimum clinically relevant change is considered 1 point in the Brog scale and 10 mm in VAS.
Interventions
Sponsors
Fakultni Nemocnice Hradec Kralove
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability of a single dose of inhaled furosemide assessed as the incidence and nature of all reported treatment-related adverse events. | — |
Secondary
| Measure | Time frame |
|---|---|
| The effect of examined substances to suppress dyspnoea will be evaluated by changing to a visually analog scale (VAS) and the Borg scale. Changes on both steps will be evaluated statistically at the level of 5% probability and it will be determined whether the changes have achieved minimum clinically relevant changes against the default values. As a minimum clinically relevant change is considered 1 point in the Brog scale and 10 mm in VAS. | — |
Countries
Czechia
Outcome results
None listed